<DOC>
	<DOCNO>NCT02923154</DOCNO>
	<brief_summary>The purpose study investigate efficacy , safety , tolerability pharmacokinetics multiple oral administration MT-3995 patient NASH .</brief_summary>
	<brief_title>Efficacy Safety MT-3995 Patients With Non-Alcoholic Steatohepatitis ( NASH )</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Subjects diagnose NASH randomization Subjects conduct diet exercise therapy begin run period . Subjects give full adequate information protocol write informed consent Subjects hepatic failure previously diagnose hepatic cirrhosis Subjects alcohol dependence previously diagnose alcohol dependence Subjects chronic liver disease ( e.g. , primary sclerosing cholangitis , alcoholic liver damage , hemochromatosis , Wilson 's disease ) Presence , history , family history long QT syndrome Torsades de Pointes Subjects heart failure ( New York Heart Association Class IIIIV )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>NASH</keyword>
</DOC>